Iovance Biotherapeutics, Inc. reported $325M of revenue over the trailing twelve months, +35% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $325M (to Q2 2026). Net income: −$290M, trailing twelve months to Q2 2026. Free cash flow: −$296M, trailing twelve months to Q2 2026. Operating margin: −98%, trailing twelve months to Q2 2026.

IOVAIovance Biotherapeutics, Inc.

Healthcare

$14.61+613% 1Y

$14.61

$1.8152 weeks$14.79

IOVA as reported

Iovance Biotherapeutics, Inc. reported $325M of revenue over the trailing twelve months, +35% on the year before. 10 reported series are charted on this page, each one as filed.

$325M

Revenue, trailing twelve months · to Q2 2026 · +35% against the twelve months before

Net income: −$290M
Net income · −26% year on year · trailing twelve months to Q2 2026
Free cash flow: −$296M
Free cash flow · −8.4% year on year · trailing twelve months to Q2 2026
Operating margin: −98%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IOVA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$325M	+35%	Q2 2026
Net income	−$290M	−26%	Q2 2026
EPS	−$1.22	n/a	Q2 2025 · 4 quarters behind
Gross margin	47%	n/a	Q2 2026
Operating margin	−98%	n/a	Q2 2026
Net margin	−94%	n/a	Q2 2026
ROE	−50%	n/a	Q2 2026
ROA	−39%	n/a	Q2 2026
ROIC	−78%	n/a	Q1 2026
Free cash flow	−$296M	−8.4%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.